Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 8—August 2024
Synopsis

Systematic Review of Prevalence of Histoplasma Antigenuria in Persons with HIV in Latin America and Africa

Preethiya Sekar, Gila Hale, Jane Gakuru, David B. Meya, David R. Boulware, Jayne Ellis, Elizabeth Nalintya, Nathan C. Bahr, and Radha RajasinghamComments to Author 
Author affiliations: University of Minnesota, Minneapolis, Minnesota, USA (P. Sekar, D.R. Boulware, N.C. Bahr, R. Rajasingham); Makerere University Infectious Diseases Institute, Kampala, Uganda (G. Hale, J. Gakuru, D.B. Meya, E. Nalintya); London School of Hygiene and Tropical Medicine, London, UK (J. Ellis); University of Kansas, Kansas City, Kansas, USA (N.C. Bahr)

Main Article

Table

Characteristics of Histoplasma urine antigen prevalence studies included in systematic review of prevalence of Histoplasma antigenuria in persons with HIV in Latin America and Africa*

Reference Country Study design Study population Clinical status Setting Test type† No. participants No. samples tested HUA positivity, %
(14) Tanzania Cross-sectional All HIV and non-HIV Symptomatic Inpatient MV EIA 628 628 1.1
(15) Uganda Cohort Advanced HIV Asymptomatic Outpatient IMMY GM EIA 388 388 1.0
(16) Uganda Cohort Advanced HIV/meningitis Symptomatic Inpatient MV EIA 257 257 0.0
(17) South Africa Cross-sectional Advanced HIV Symptomatic Outpatient IMMY Alpha EIA 34 17 23.5
(18) South Africa Cross-sectional Advanced HIV Asymptomatic Inpatient IMMY GM EIA 189 189 5.8
(19) Cameroon Cross-sectional All HIV Asymptomatic Outpatient OIDx EIA 138 138 26.1
(20) Ghana Cross-sectional All HIV Asymptomatic Outpatient IMMY GM EIA + OIDx LFA 150 107 5.6
(21) Nigeria Cross-sectional Advanced HIV Symptomatic Outpatient IMMY GM EIA 213 41 7.3
(22) Nigeria Cross-sectional Advanced HIV Symptomatic Inpatient IMMY GM EIA 988 988 7.7
(23) Mexico Cohort Advanced HIV Symptomatic Inpatient IMMY Alpha EIA 288 288 21.5
(24) Brazil Cohort Advanced HIV Asymptomatic Inpatient IMMY Alpha EIA 106 106 3.8
(25) Colombia Cross- sectional Advanced HIV Symptomatic Inpatient IMMY Alpha EIA 172 172 29.1
(26) Colombia Cross-sectional Advanced HIV Asymptomatic Outpatient CDC ELISA 768 154 20.1
(27) Panama, Honduras, Nicaragua Cross-sectional All HIV Symptomatic Inpatient IMMY GM EIA 4453 1343 20.0
(28) Trinidad Cross-sectional HIV Asymptomatic Outpatient IMMY GM EIA + OIDx LFA 280 280 6.4

*EIA, enzyme immunoessay; GM, galactomannan; HUA, histoplasma urine antigen; LFA, lateral flow assay; OIDx, Optimum Imaging Diagnostics †Test manufacturers and types: MV, MiraVista Diagnostics EIA (https://miravistalabs.com); IMMY Alpha and GM EIAs (https://www.immy.com); OIDx, Optimum Imaging Diagnostics LFA (https://optimumimaging.com). ‡All HIV refers to participants with HIV who were not stratified by CD4 or limited to CD4 counts <200, such as persons in advanced HIV cohorts.

Main Article

References
  1. Adenis  AA. AIDS-related histoplasmosis in Latin America [abstract]. Med Mycol. 2018;56(Suppl 2):S7.
  2. Samayoa  B, Roy  M, Cleveland  AA, Medina  N, Lau-Bonilla  D, Scheel  CM, et al. High mortality and coinfection in a prospective cohort of human immunodeficiency virus/acquired immune deficiency syndrome patients with histoplasmosis in Guatemala. Am J Trop Med Hyg. 2017;97:42–8. DOIPubMedGoogle Scholar
  3. Adenis  AA, Valdes  A, Cropet  C, McCotter  OZ, Derado  G, Couppie  P, et al. Burden of HIV-associated histoplasmosis compared with tuberculosis in Latin America: a modelling study. Lancet Infect Dis. 2018;18:1150–9. DOIPubMedGoogle Scholar
  4. Ashraf  N, Kubat  RC, Poplin  V, Adenis  AA, Denning  DW, Wright  L, et al. Re-drawing the maps for endemic mycoses. Mycopathologia. 2020;185:843–65. DOIPubMedGoogle Scholar
  5. Adenis  A, Nacher  M, Hanf  M, Basurko  C, Dufour  J, Huber  F, et al. Tuberculosis and histoplasmosis among human immunodeficiency virus-infected patients: a comparative study. Am J Trop Med Hyg. 2014;90:216–23. DOIPubMedGoogle Scholar
  6. Villareal  K, Price  A, Pasqualotto  AC, Bahr  NC. The current and future states of diagnostic tests for histoplasmosis with a focus on people with HIV and disseminated histoplasmosis. J Fungi (Basel). 2023;9:793793. DOIPubMedGoogle Scholar
  7. Martínez-Gamboa  A, Niembro-Ortega  MD, Torres-González  P, Santiago-Cruz  J, Velázquez-Zavala  NG, Rangel-Cordero  A, et al. Diagnostic accuracy of antigen detection in urine and molecular assays testing in different clinical samples for the diagnosis of progressive disseminated histoplasmosis in patients living with HIV/AIDS: A prospective multicenter study in Mexico. PLoS Negl Trop Dis. 2021;15:e0009215. DOIPubMedGoogle Scholar
  8. Cáceres  DH, Gómez  BL, Tobón  ÁM, Chiller  TM, Lindsley  MD. Evaluation of OIDx Histoplasma urinary antigen EIA. Mycopathologia. 2022;187:129–31. DOIPubMedGoogle Scholar
  9. Torres-González  P, Niembro-Ortega  MD, Martínez-Gamboa  A, Ahumada-Topete  VH, Andrade-Villanueva  J, Araujo-Meléndez  J, et al. Diagnostic accuracy cohort study and clinical value of the Histoplasma urine antigen (ALPHA Histoplasma EIA) for disseminated histoplasmosis among HIV infected patients: A multicenter study. PLoS Negl Trop Dis. 2018;12:e0006872. DOIPubMedGoogle Scholar
  10. Theel  ES, Jespersen  DJ, Harring  J, Mandrekar  J, Binnicker  MJ. Evaluation of an enzyme immunoassay for detection of Histoplasma capsulatum antigen from urine specimens. J Clin Microbiol. 2013;51:3555–9. DOIPubMedGoogle Scholar
  11. Goldet  G, Howick  J. Understanding GRADE: an introduction. J Evid Based Med. 2013;6:50–4. DOIPubMedGoogle Scholar
  12. Caceres  DH, Knuth  M, Derado  G, Lindsley  MD. Diagnosis of progressive disseminated histoplasmosis in advanced HIV: a meta-analysis of assay analytical performance. J Fungi (Basel). 2019;5:76. DOIPubMedGoogle Scholar
  13. Abdallah  W, Myint  T, LaRue  R, Minderman  M, Gunn  S, Wheat  LJ, et al. Diagnosis of histoplasmosis using the MVista Histoplasma galactomannan antigen qualitative lateral flow-based immunoassay: a multicenter study. Open Forum Infect Dis. 2021;8:ofab454.
  14. Lofgren  SM, Kirsch  EJ, Maro  VP, Morrissey  AB, Msuya  LJ, Kinabo  GD, et al. Histoplasmosis among hospitalized febrile patients in northern Tanzania. Trans R Soc Trop Med Hyg. 2012;106:504–7. DOIPubMedGoogle Scholar
  15. Sekar  P, Nalintya  E, Kwizera  R, Mukashyaka  C, Niyonzima  G, Namakula  LO, et al. Prevalence of Histoplasma antigenuria among outpatient cohort with advanced HIV in Kampala, Uganda. J Fungi (Basel). 2023;9:757. DOIPubMedGoogle Scholar
  16. Bahr  NC, Sarosi  GA, Meya  DB, Bohjanen  PR, Richer  SM, Swartzentruber  S, et al. Seroprevalence of histoplasmosis in Kampala, Uganda. Med Mycol. 2016;54:295–300. DOIPubMedGoogle Scholar
  17. Schwartz  IS, Kenyon  C, Lehloenya  R, Claasens  S, Spengane  Z, Prozesky  H, et al. AIDS-related endemic mycoses in western Cape, South Africa, and clinical mimics: a cross-sectional study of adults with advanced HIV and recent-onset, widespread skin lesions. Open Forum Infect Dis. 2017;4:ofx186. DOIPubMedGoogle Scholar
  18. van Schalkwyk  E, Mhlanga  M, Maphanga  TG, Mpembe  RS, Shillubane  A, Iyaloo  S, et al. Screening for invasive fungal disease using non-culture-based assays among inpatients with advanced HIV disease at a large academic hospital in South Africa. Mycoses. 2020;63:478–87. DOIPubMedGoogle Scholar
  19. Kuate  MPN, Nyasa  R, Mandengue  C, Tendongfor  N, Bongomin  F, Denning  DW. Screening for acute disseminated histoplasmosis in HIV disease using urinary antigen detection enzyme immunoassay: A pilot study in Cameroon. J Microbiol Methods. 2021;185:106226. DOIPubMedGoogle Scholar
  20. Ocansey  BK, Otoo  B, Asamoah  I, Ganu  V, Berko  KP, Oladele  O, et al. Cryptococcal and Histoplasma antigen screening among people with human immunodeficiency virus in Ghana and comparative analysis of OIDx Histoplasma lateral flow assay and IMMY Histoplasma enzyme immunoassay. Open Forum Infect Dis. 2022;9:ofac277.
  21. Ekeng  BE, Oladele  RO, Emanghe  UE, Ochang  EA, Mirabeau  TY. Prevalence of histoplasmosis and molecular characterization of Histoplasma species in patients with presumptive pulmonary tuberculosis in Calabar, Nigeria. Open Forum Infect Dis. 2022;9:ofac368.
  22. Oladele  RO, Osaigbovo  II, Akanmu  AS, Adekanmbi  OA, Ekeng  BE, Mohammed  Y, et al. Prevalence of histoplasmosis among persons with advanced HIV disease, Nigeria. Emerg Infect Dis. 2022;28:2261–9. DOIPubMedGoogle Scholar
  23. Torres-González  P, Niembro-Ortega  MD, Martínez-Gamboa  A, Ahumada-Topete  VH, Andrade-Villanueva  J, Araujo-Meléndez  J, et al. Diagnostic accuracy cohort study and clinical value of the Histoplasma urine antigen (ALPHA Histoplasma EIA) for disseminated histoplasmosis among HIV infected patients: A multicenter study. PLoS Negl Trop Dis. 2018;12:e0006872. DOIPubMedGoogle Scholar
  24. Vidal  JE, Werlang  PC, Muniz  BM, Rego  CM, Barbalho  RE, Baptista  AM, et al. Combining urine antigen and blood polymerase chain reaction for the diagnosis of disseminated histoplasmosis in hospitalized patients with advanced HIV disease. Med Mycol. 2021;59:916–22. DOIPubMedGoogle Scholar
  25. Hoyos Pulgarin  JA, Alzate Piedrahita  JA, Moreno Gómez  GA, Sierra Palacio  JF, Ordoñez  KM, Arias Ramos  D. Closing gaps in histoplasmosis: clinical characteristics and factors associated with probable/histoplasmosis in HIV/AIDS hospitalized patients, a retrospective cross-sectional study in two tertiary centers in Pereira, Colombia. AIDS Res Ther. 2021;18:51. DOIPubMedGoogle Scholar
  26. Caceres  DH, Zuluaga  A, Arango-Bustamante  K, de Bedout  C, Tobón  ÁM, Restrepo  Á, et al. Implementation of a training course increased the diagnosis of histoplasmosis in Colombia. Am J Trop Med Hyg. 2015;93:662–7. DOIPubMedGoogle Scholar
  27. Caceres  DH, Arauz  AB, Flores  C, Santiago  E, Montoya  S, Saenz  C, et al. Implementation of rapid diagnostics assays for detection of histoplasmosis and cryptococcosis in central american people living with HIV. Mycoses. 2021;64:1396–401. DOIPubMedGoogle Scholar
  28. Edwards  RJ, Todd  S, Edwards  J, Samaroo-Francis  W, Lyons  N, Boyce  G, et al. The incidence of histoplasmosis and cryptococcal antigenemia among patients attending a large HIV clinic in Trinidad. Diagn Microbiol Infect Dis. 2023;106:115952. DOIPubMedGoogle Scholar

Main Article

Page created: May 22, 2024
Page updated: July 16, 2024
Page reviewed: July 16, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external